Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut 2025-11-07 08:10
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) 2025-10-20 08:10
CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR 2025-05-07 08:00
CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress 2025-03-27 19:55
CStone to Showcase Five Latest Research Achievements at AACR 2025 2025-03-26 08:15
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer 2025-03-24 08:15
CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL 2025-03-06 08:10
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody 2025-03-04 08:10
CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA 2025-02-25 12:10
CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline 2025-02-10 12:20
CStone Partners with SteinCares to Market Sugemalimab in Latin America 2025-01-27 12:30
CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody 2024-12-23 08:00
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting 2024-12-09 08:20
CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK 2024-10-31 13:00
CStone Reports 2024 Interim Results and Recent Corporate Updates 2024-08-23 22:20
CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer 2024-07-26 20:16
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC 2024-06-02 08:24
CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website 2024-05-24 13:00
CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates 2024-03-27 22:00
CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer 2024-03-15 12:10